<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61630</article-id><article-id pub-id-type="doi">10.7554/eLife.61630</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-200250"><name><surname>Glykofridis</surname><given-names>Iris E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1829-2403</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203280"><name><surname>Knol</surname><given-names>Jaco C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203281"><name><surname>Balk</surname><given-names>Jesper A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203282"><name><surname>Westland</surname><given-names>Denise</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203283"><name><surname>Pham</surname><given-names>Thang V</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203284"><name><surname>Piersma</surname><given-names>Sander R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203285"><name><surname>Lougheed</surname><given-names>Sinéad M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203286"><name><surname>Derakhshan</surname><given-names>Sepide</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203287"><name><surname>Veen</surname><given-names>Puck</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203288"><name><surname>Rooimans</surname><given-names>Martin A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203289"><name><surname>van Mil</surname><given-names>Saskia E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218070"><name><surname>Böttger</surname><given-names>Franziska</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203290"><name><surname>Poddighe</surname><given-names>Pino J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203291"><name><surname>van de Beek</surname><given-names>Irma</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203292"><name><surname>Drost</surname><given-names>Jarno</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203293"><name><surname>Zwartkruis</surname><given-names>Fried JT</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203294"><name><surname>de Menezes</surname><given-names>Renee X</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203295"><name><surname>Meijers-Heijboer</surname><given-names>Hanne EJ</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203296"><name><surname>Houweling</surname><given-names>Arjan C</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-203297"><name><surname>Jimenez</surname><given-names>Connie R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-203298"><name><surname>Wolthuis</surname><given-names>Rob MF</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3109-1588</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Clinical Genetics, Cancer Center Amsterdam</institution>, <institution>Amsterdam UMC</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff2"><institution content-type="dept">Medical Oncology, Cancer Center Amsterdam</institution>, <institution>Amsterdam UMC</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff3"><institution content-type="dept">Molecular Cancer Research</institution>, <institution>University Medical Center Utrecht</institution>, <addr-line><named-content content-type="city">Utrecht</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff4"><institution content-type="dept">Oncode Institute</institution>, <institution>Princess Máxima Center for Pediatric Oncology</institution>, <addr-line><named-content content-type="city">Utrecht</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff5"><institution content-type="dept">Clinical Genetics</institution>, <institution>Amsterdam UMC</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff6"><institution content-type="dept">Biostatistics Unit</institution>, <institution>NKI-AvL</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-31092"><name><surname>Zwart</surname><given-names>Wilbert</given-names></name><role>Reviewing editor</role><aff><institution>Netherlands Cancer Institute</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>i.glykofridis@amsterdamumc.nl</email> (IG);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>c.jimenez@amsterdamumc.nl</email> (CJ);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>r.wolthuis@amsterdamumc.nl</email> (RW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>01</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e61630</elocation-id><history><date date-type="received"><day>31</day><month>07</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Glykofridis et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Glykofridis et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61630-v1.pdf"/><abstract><p>Germline inactivating mutations in Folliculin (FLCN) cause Birt–Hogg–Dubé (BHD) syndrome, a rare autosomal dominant disorder predisposing to kidney tumors. FLCN is a conserved, essential gene linked to diverse cellular processes but the mechanisms by which FLCN prevents kidney cancer remain unknown. Here we show that deleting FLCN activates TFE3, upregulating its downstream E-box genes in human renal tubular epithelial cells (RPTEC/TERT1), including RRAGD and GPNMB, without modifying mTORC1 activity. Surprisingly, deletion of FLCN or its binding partners FNIP1/FNIP2 also induces interferon response genes, but independently of interferon. Mechanistically, FLCN loss promotes STAT2 recruitment to chromatin and slows cellular proliferation. Our integrated analysis identifies STAT1/2 signaling as a novel target of FLCN in renal cells and BHD tumors. STAT1/2 activation appears to counterbalance TFE3-directed hyper-proliferation and may influence the immune response. These findings shed light on unique roles of FLCN in human renal tumorigenesis and pinpoint candidate prognostic biomarkers.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>KWF Kankerbestrijding/Alpe d'Huzes Bas Mulder Award</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Drost</surname><given-names>Jarno</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Foundation Children Cancer Free</institution></institution-wrap></funding-source><award-id>Core Funding</award-id><principal-award-recipient><name><surname>Derakhshan</surname><given-names>Sepide</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Oncode Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Drost</surname><given-names>Jarno</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Cancer Center Amsterdam</institution></institution-wrap></funding-source><award-id>CCA2018-5-51</award-id><principal-award-recipient><name><surname>Glykofridis</surname><given-names>Iris E</given-names></name><name><surname>Wolthuis</surname><given-names>Rob MF</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Cancer Center Amsterdam</institution></institution-wrap></funding-source><award-id>Core Funding Mass Spectrometry Infrastructure</award-id><principal-award-recipient><name><surname>Knol</surname><given-names>Jaco C</given-names></name><name><surname>Pham</surname><given-names>Thang V</given-names></name><name><surname>Piersma</surname><given-names>Sander R</given-names></name><name><surname>Jimenez</surname><given-names>Connie R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: BHD T1 and BHD T2 tumor samples were obtained with informed consent. Both tissues are leftover material from surgery and are stored in our BHD biobank (2019.359 at AmsterdamUMC).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Data files of transcriptomic and proteomic data are provided as supplementary table 1. Raw data files deposited on Dryad Digital Repository (RNAseq): doi:10.5061/dryad.6djh9w0zsProteomeXchange (Mass Spec) under accession number PXD021346</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Glykofridis et al</collab></person-group><year iso-8601-date="2020">2020</year><source>RNAseq raw counts_FLCN positive vs. FLCN negative RPTECs</source><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5061/dryad.6djh9w0zs">http://dx.doi.org/10.5061/dryad.6djh9w0zs</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.6djh9w0zs</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Glykofridis et al</collab></person-group><year iso-8601-date="2020">2020</year><source>Mass Spec data_FLCN positive vs. FLCN negative RPTECs</source><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD021346">https://www.ebi.ac.uk/pride/archive/projects/PXD021346</ext-link><comment>ProteomeXchange, PXD021346</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-61630-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>